

Hacking the Lung Cancer Genetic Code

Written by The Life Science Feed Editorial Team · Published 29 May 2026 · Edited by James Carter

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Soda M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*. 2007;448:561-566
doi:10.1038/nature05945
2. Shaw AT et al. ALEX: alectinib vs crizotinib in ALK-positive NSCLC. *N Engl J Med*. 2017;377:829-838
3. Mok TS et al. FLAURA: osimertinib vs gefitinib/erlotinib in EGFR-mutant NSCLC. *N Engl J Med*. 2017;376:629-640
4. Lin JJ et al. CROWN: lorlatinib vs crizotinib in ALK-positive NSCLC. *N Engl J Med*. 2020;383:2018-2029
5. Dilon A et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med*. 2018;378:731-739

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com